Introduction: Although 4 mast cell mediators can be routinely measured, the results of initial testing to evaluate symptoms of mast cell activation have not been widely reported. Objective: We examined the results of mast cell mediator tests used to assess patients with mast cell activation symptoms during a 5-year time span. Methods: After excluding patients with alternative diagnoses, records of 108 patients were reviewed for initial mediator test results. Mediators included serum tryptase plus urinary N-methyl histamine (N-MH), leukotriene (LT)E4, and 11β-prostaglandin (PG) F2α or 2,3-dinor-11β-PGF2α (BPG). Results: Most commonly, either a single measured elevation of 1 mediator (48.1%) or elevations of 2 (33.3%) mediators was found at baseline, during symptoms or at both time points. Elevated levels of a single mediator in order of frequency were: BPG > tryptase > LTE4 > N-MH, and for two mediators: BPG + tryptase (n = 16 cases) > BPG + LTE4 (n = 9) > BPG + N-MH (n = 6). Elevations in 3 mediators (n = 8) or 4 mediators (n = 2) were much less frequent. Monoclonal mast cell activation syndrome (n = 6), and systemic and cutaneous mastocytosis (n = 4) were also infrequent. Baseline plus symptom-associated tryptase values were obtained in only 7 patients. Conclusions: This survey suggests that elevations of 1 or 2 mediators are the most common (total 81.4% of cases) findings from initial tests for mast cell activation. Elevated levels of BPG were most commonly found both singly and in combination with other mediators, followed by the finding of elevated levels of tryptase. Baseline plus symptom-associated tryptase levels were measured in only a minority of patients.

1.
Orfanos
C
,
Stuttgen
G
.
[Electron microscopic observations on mast cell degranulation in diffuse mastocytosis in man]
.
[German]
.
Arch Klin Exp Dermatol
.
1962
;
214
:
521
48
.
[PubMed]
0300-8614
2.
Soter
NA
,
Wasserman
SI
.
Physical urticaria/angioedema: an experimental model of mast cell activation in humans
.
J Allergy Clin Immunol
.
1980
Nov
;
66
(
5
):
358
65
.
[PubMed]
0091-6749
3.
Valent
P
,
Akin
C
,
Arock
M
,
Brockow
K
,
Butterfield
JH
,
Carter
MC
, et al
Definitions, criteria and global classification of mast cell disorders with special reference to mast cell activation syndromes: a consensus proposal
.
Int Arch Allergy Immunol
.
2012
;
157
(
3
):
215
25
.
[PubMed]
1018-2438
4.
Afrin
LB
.
Mast cell activation disease and the modern epidemic of chronic inflammatory disease
.
Transl Res
.
2016
Aug
;
174
:
33
59
.
[PubMed]
1931-5244
5.
Afrin
LB
,
Pöhlau
D
,
Raithel
M
,
Haenisch
B
,
Dumoulin
FL
,
Homann
J
, et al
Mast cell activation disease: an underappreciated cause of neurologic and psychiatric symptoms and diseases
.
Brain Behav Immun
.
2015
Nov
;
50
:
314
21
.
[PubMed]
0889-1591
6.
Cardet
JC
,
Castells
MC
,
Hamilton
MJ
.
Immunology and clinical manifestations of non-clonal mast cell activation syndrome
.
Curr Allergy Asthma Rep
.
2013
Feb
;
13
(
1
):
10
8
.
[PubMed]
1529-7322
7.
Schaefer
M
,
Harke
R
,
Denke
C
.
Open-Label Placebos Improve Symptoms in Allergic Rhinitis: A Randomized Controlled Trial
.
Psychother Psychosom
.
2016
;
85
(
6
):
373
4
.
[PubMed]
0033-3190
8.
Wechsler
ME
,
Kelley
JM
,
Boyd
IO
,
Dutile
S
,
Marigowda
G
,
Kirsch
I
, et al
Active albuterol or placebo, sham acupuncture, or no intervention in asthma
.
N Engl J Med
.
2011
Jul
;
365
(
2
):
119
26
.
[PubMed]
0028-4793
9.
Napadow
V
,
Li
A
,
Loggia
ML
,
Kim
J
,
Mawla
I
,
Desbordes
G
, et al
The imagined itch: brain circuitry supporting nocebo-induced itch in atopic dermatitis patients
.
Allergy
.
2015
Nov
;
70
(
11
):
1485
92
.
[PubMed]
0105-4538
10.
Bornschein
S
,
Hausteiner
C
,
Römmelt
H
,
Nowak
D
,
Förstl
H
,
Zilker
T
.
Double-blind placebo-controlled provocation study in patients with subjective Multiple Chemical Sensitivity (MCS) and matched control subjects
.
Clin Toxicol (Phila)
.
2008
Jun
;
46
(
5
):
443
9
.
[PubMed]
1556-3650
11.
Lyons
JJ
,
Yu
X
,
Hughes
JD
,
Le
QT
,
Jamil
A
,
Bai
Y
, et al
Elevated basal serum tryptase identifies a multisystem disorder associated with increased TPSAB1 copy number
.
Nat Genet
.
2016
Dec
;
48
(
12
):
1564
9
.
[PubMed]
1061-4036
12.
Sperr
WR
,
El-Samahi
A
,
Kundi
M
,
Girschikofsky
M
,
Winkler
S
,
Lutz
D
, et al
Elevated tryptase levels selectively cluster in myeloid neoplasms: a novel diagnostic approach and screen marker in clinical haematology
.
Eur J Clin Invest
.
2009
Oct
;
39
(
10
):
914
23
.
[PubMed]
0014-2972
13.
Valent
P
,
Akin
C
,
Bonadonna
P
,
Hartmann
K
,
Brockow
K
,
Niedoszytko
M
, et al
Proposed diagnostic algorithm for patient with suspected mast cell activation syndrome
.
J Allergy Clin Immunol Pract
.
2019
Apr
;
7
(
4
):
1125
1133.e1
.
[PubMed]
2213-2198
14.
Carter
MC
,
Metcalfe
DD
,
Matito
A
,
Escribano
L
,
Butterfield
JH
,
Schwartz
LB
, et al
Adverse reactions to drugs and biologics in patients with clonal mast cell disorders: A work group report of the mast cells disorder committee, American Academy of Allergy
.
J Allergy Clin Immunol
.
2019
Mar
;
143
(
3
):
880
93
.
[PubMed]
0091-6749
15.
Ravi
A
,
Butterfield
J
,
Weiler
CR
.
Mast cell activation syndrome: improved identification by combined determinations of serum tryptase and 24-hour urine 11β-prostaglandin2α
.
J Allergy Clin Immunol Pract
.
2014
Nov-Dec
;
2
(
6
):
775
8
.
[PubMed]
2213-2198
16.
Butterfield
JH
,
Weiler
CR
.
Prevention of mast cell activation disorder-associated clinical sequelae of excessive prostaglandin D(2) production
.
Int Arch Allergy Immunol
.
2008
;
147
(
4
):
338
43
.
[PubMed]
1018-2438
17.
Akin
C
,
Valent
P
,
Metcalfe
DD
.
Mast cell activation syndrome: proposed diagnostic criteria
.
J Allergy Clin Immunol
.
2010
Dec
;
126
(
6
):
1099
104.e4
.
[PubMed]
0091-6749
18.
Valent
P
.
Mast cell activation syndromes: definition and classification
.
Allergy
.
2013
Apr
;
68
(
4
):
417
24
.
[PubMed]
0105-4538
19.
van der Donk
EM
,
Blok
W
,
Kok
PT
,
Bruijnzeel
PL
.
Leukotriene C4 formation by enriched human basophil preparations from normal and asthmatic subjects
.
Prostaglandins Leukot Essent Fatty Acids
.
1991
Sep
;
44
(
1
):
11
7
.
[PubMed]
0952-3278
20.
Ugajin
T
,
Satoh
T
,
Kanamori
T
,
Aritake
K
,
Urade
Y
,
Yokozeki
H
.
FcεRI, but not FcγR, signals induce prostaglandin D2 and E2 production from basophils
.
Am J Pathol
.
2011
Aug
;
179
(
2
):
775
82
.
[PubMed]
0002-9440
21.
Ono
E
,
Taniguchi
M
,
Mita
H
,
Fukutomi
Y
,
Higashi
N
,
Miyazaki
E
, et al
Increased production of cysteinyl leukotrienes and prostaglandin D2 during human anaphylaxis
.
Clin Exp Allergy
.
2009
Jan
;
39
(
1
):
72
80
.
[PubMed]
0954-7894
22.
Steinke
JW
,
Negri
J
,
Baker
MG
,
Payne
S
,
Borish
L
,
Feng
X
.
Eosinophil production of PGD2 in aspirin-exacerbated respiratory disease
.
J Allergy Clin Immunol
.
2016
;
138
:
1089
97
.
[PubMed]
0091-6749
23.
Tanaka
K
,
Ogawa
K
,
Sugamura
K
,
Nakamura
M
,
Takano
S
,
Nagata
K
.
Cutting edge: differential production of prostaglandin D2 by human helper T cell subsets
.
J Immunol
.
2000
Mar
;
164
(
5
):
2277
80
.
[PubMed]
0022-1767
24.
Lewis
RA
,
Soter
NA
,
Diamond
PT
,
Austen
KF
,
Oates
JA
,
Roberts
LJ
 2nd
.
Prostaglandin D2 generation after activation of rat and human mast cells with anti-IgE
.
J Immunol
.
1982
Oct
;
129
(
4
):
1627
31
.
[PubMed]
0022-1767
25.
Shimura
C
,
Satoh
T
,
Igawa
K
,
Aritake
K
,
Urade
Y
,
Nakamura
M
, et al
Dendritic cells express hematopoietic prostaglandin D synthase and function as a source of prostaglandin D2 in the skin
.
Am J Pathol
.
2010
Jan
;
176
(
1
):
227
37
.
[PubMed]
0002-9440
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.